New Federal Clinical Standards for Perimenopause and Menopause Care Released

The U.S. Department of Veterans Affairs and the Department of Defense have jointly released evidence-based clinical practice guidelines for the diagnosis and management of perimenopause and menopause, according to the Department of Defense. The document establishes a federal-level U.S. reference point for the care of patients in this transition, including those served through the VA and military health systems.

Scope of the guideline

The recommendations target five clinical domains: vasomotor symptoms, bone health, sleep disturbances, cardiovascular risk, and genitourinary health. Each domain is addressed as a separate decision pathway rather than folded into a single undifferentiated "menopause" protocol. The Department of War, in its announcement titled "New Clinical Guideline Helps Keep Women 'Optimized for the Fight'," positioned the document as both a clinical and force-readiness instrument, a framing that signals how the guideline is intended to be used inside the military health system.

What changes for clinicians outside the VA and DoD

For civilian and private-sector providers, the release creates a federal benchmark against which existing menopause protocols will be compared. Insurers, telehealth menopause services, and hospital systems typically align screening thresholds and treatment algorithms with federal documents over time. The five named domains represent the confirmed scope of the guideline. Specific screening tools, pharmacologic algorithms, estradiol-level thresholds, and contraindication language are not detailed in the public announcement and require direct review of the full document before being cited in clinical practice.

What to verify before applying the guideline

• Exact recommendation language for menopausal hormone therapy, including any estradiol-level cutoffs and contraindications.
• Specific guidance on non-hormonal pharmacologic options for vasomotor symptoms.
• Bone health screening intervals and DEXA recommendations.
• Genitourinary syndrome of menopause (GSM) treatment algorithms.
• Cardiovascular risk assessment tools and thresholds for specialist referral.

Until the full text and supporting evidence reviews are reviewed, treat the five named domains as the confirmed scope. Do not extrapolate clinical recommendations beyond what is published.